Cross-genotypic examination of hepatitis c virus polymerase inhibitors reveals a novel mechanism of action for thumb binders

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7215-7224

  Eltahla, Auda A ^a   Tay, Enoch ^b   Douglas, Mark W ^b   White, Peter A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2' METHYLCYTIDINE; ANTIVIRUS AGENT; FILIBUVIR; JTK 109; LOMIBUVIR; NESBUVIR; RECOMBINANT ENZYME; RNA DIRECTED RNA POLYMERASE INHIBITOR; SETROBUVIR; TEGOBUVIR; UNCLASSIFIED DRUG; 2-(4-(4'-CHLORO-4-(2-OXOPYRROLIDIN-1-YL)BIPHENYL-2-YLMETHOXY)-2-FLUOROPHENYL)-1-CYCLOHEXYL-1H-BENZIMIDAZOLE-5-CARBOXYLIC ACID; BENZIMIDAZOLE DERIVATIVE; BENZOFURAN DERIVATIVE; CYCLOHEXANOL DERIVATIVE; ENZYME INHIBITOR; PURINE DERIVATIVE; PYRIDAZINE DERIVATIVE; PYRONE DERIVATIVE; RECOMBINANT PROTEIN; RNA DIRECTED RNA POLYMERASE; SULFONAMIDE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CELLS; CONTROLLED STUDY; DRUG BINDING SITE; DRUG SCREENING; ENZYME ACTIVITY; ENZYME INHIBITION; HEPATITIS C VIRUS SUBTYPE 1B; HEPATITIS C VIRUS SUBTYPE 2A; HEPATITIS C VIRUS SUBTYPE 3A; IC50; IN VITRO STUDY; NONHUMAN; REPLICON; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS; HUMAN; STRUCTURE ACTIVITY RELATION;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; BENZOFURANS; CYCLOHEXANOLS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GENOTYPE; HEPACIVIRUS; HUMANS; PURINES; PYRIDAZINES; PYRONES; RECOMBINANT PROTEINS; REPLICON; RNA REPLICASE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; THIOPHENES; TRIAZOLES; VIRAL PROTEINS;

EID: 84912084604     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03699-14     Document Type: Article

References (72)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342. http://dx .doi.org/10.1002/hep.26141.
2. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973. http://dx.doi.org/10.1002/hep.20819.
3. Manns MP, Wedemeyer H, Cornberg M. 2006. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55:1350-1359. http://dx.doi .org/10.1136/gut.2005.076646.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
5. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364:1195-1206. http://dx.doi.org/10.1056/NEJMoa1010494.
6. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. 2012. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56(Suppl 1):S88-S100. http://dx.doi.org/10.1016/S0168-8278(12)60010-5.
7. Jacobson I, Dore G, Foster G, Fried M, Radu M, Rafalskiy V, Moroz L, Craxi A, Peeters M, Lenz O. 2013. Simeprevir (TMC435) with peginterferon/ ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. J. Hepatol. 58:S574.
8. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. 2013. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 368:34-44. http: //dx.doi.org/10.1056/NEJMoa1208953.
9. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368:1878-1887. http://dx.doi.org/10.1056/NEJMoa1214853.
10. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, DeJesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. 2013. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for noncirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect. Dis. 13:401-408. http://dx.doi.org/10.1016/S1473-3099(13)70033-1.
11. Scheel TK, Rice CM. 2013. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 19:837-849. http: //dx.doi.org/10.1038/nm.3248.
12. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R, Rey FA. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 96:13034-13039. http://dx.doi.org/10.1073/pnas.96.23.13034.
13. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. 1999. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6:937-943. http://dx.doi.org/10.1038/13305.
14. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K, Miyano M. 1999. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417-1426. http://dx.doi.org/10.1016 /S0969-2126(00)80031-3.
15. Caillet-Saguy C, Simister PC, Bressanelli S. 2011. An objective assessment of conformational variability in complexes of hepatitis C virus polymerase with non-nucleoside inhibitors. J. Mol. Biol. 414:370-384. http: //dx.doi.org/10.1016/j.jmb.2011.10.001.
16. Haudecoeur R, Peuchmaur M, Ahmed-Belkacem A, Pawlotsky JM, Boumendjel A. 2013. Structure-activity relationships in the development of allosteric hepatitisCvirus RNA-dependentRNApolymerase inhibitors: ten years of research. Med. Res. Rev. 33:934-984. http://dx.doi.org/10 .1002/med.21271.
17. Bartenschlager R, Lohmann V, Penin F. 2013. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat. Rev. Microbiol. 11:482-496. http://dx.doi.org/10.1038/nrmicro3046.
18. Chan L, Das SK, Reddy TJ, Poisson C, Proulx M, Pereira O, Courchesne M, Roy C, Wang W, Siddiqui A. 2004. Discovery of thio-phene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. 1. Sulfonamides. Bioorg. Med. Chem. Lett. 14:793-796. http://dx.doi.org/10.1016/j.bmcl.2003.10.067.
19. Li H, Tatlock J, Linton A, Gonzalez J, Jewell T, Patel L, Ludlum S, Drowns M, Rahavendran SV, Skor H. 2009. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl) ethyl)-3-((5,7-dimethyl-[1,2,4] triazolo [1,5-a] pyrimidin-2-yl) methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J. Med. Chem. 52:1255-1258. http: //dx.doi.org/10.1021/jm8014537.
20. Gopalsamy A, Chopra R, Lim K, Ciszewski G, Shi M, Curran KJ, Sukits SF, Svenson K, Bard J, Ellingboe JW. 2006. Discovery of proline sulfonamides as potent and selective hepatitis C virus NS5b polymerase inhibitors. Evidence for a new NS5b polymerase binding site. J. Med. Chem. 49:3052-3055. http://dx.doi.org/10.1021/jm060168g.
21. Nyanguile O, Pauwels F, Van den Broeck W, Boutton CW, Quirynen L, Ivens T, van der Helm L, Vandercruyssen G, Mostmans W, Delouvroy F, Dehertogh P, Cummings MD, Bonfanti JF, Simmen KA, Raboisson P. 2008. 1,5-Benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors. Antimicrob. Agents Chemother. 52:4420-4431. http://dx.doi.org/10.1128/AAC.00669-08.
22. Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, Gu B, Silverman C, Gates AT, Nonnemacher MR, Earnshaw DL, Casper DJ, Kaura A, Baker A, Greenwood C, Gutshall LL, Maley D, DelVecchio A, Macarron R, Hofmann GA, Alnoah Z, Cheng HY, Chan G, Khandekar S, Keenan RM, Sarisky RT. 2002. Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Biol. Chem. 277:38322-38327. http: //dx.doi.org/10.1074/jbc.M205566200.
23. Kneteman NM, Howe AY, Gao T, Lewis J, Pevear D, Lund G, Douglas D, Mercer DF, Tyrrell DLJ, Immermann F. 2009. HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus. Hepatology 49:745-752. http://dx .doi.org/10.1002/hep.22717.
24. Vliegen I, Paeshuyse J, De Burghgraeve T, Lehman LS, Paulson M, Shih IH, Mabery E, Boddeker N, De Clercq E, Reiser H, Oare D, Lee WA, Zhong W, Bondy S, Purstinger G, Neyts J. 2009. Substituted imidazopyridines as potent inhibitors of HCV replication. J. Hepatol. 50:999-1009. http://dx.doi.org/10.1016/j.jhep.2008.12.028.
25. Shih IH, Vliegen I, Peng B, Yang H, Hebner C, Paeshuyse J, Purstinger G, Fenaux M, Tian Y, Mabery E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts J, Zhong W. 2011. Mechanistic characterization of GS-9190 (tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 55: 4196-4203. http://dx .doi.org/10.1128/AAC.00307-11.
26. Lohmann V, Bartenschlager R. 2014. On the history of hepatitis C virus cell culture systems. J. Med. Chem. 57:1627-1642. http://dx.doi.org/10 .1021/jm401401n.
27. Pauwels F, Mostmans W, Quirynen LM, van der Helm L, Boutton CW, Rueff AS, Cleiren E, Raboisson P, Surleraux D, Nyanguile O, Simmen KA. 2007. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J. Virol. 81:6909-6919. http://dx.doi.org /10.1128/JVI.01543-06.
28. May MM, Lorengel H, Kreuter J, Zimmermann H, Ruebsamen-Schaeff H, Urban A. 2011. RNA-dependent RNA polymerases from different hepatitis C virus genotypes reveal distinct biochemical properties and drug susceptibilities. Biochim. Biophys. Acta 1814:1325-1332. http://dx .doi.org/10.1016/j.bbapap.2011.05.006.
29. Herlihy KJ, Graham JP, Kumpf R, Patick AK, Duggal R, Shi ST. 2008. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob. Agents Chemother. 52:3523-3531. http://dx.doi.org/10 .1128/AAC.00533-08.
30. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. 2012. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 56:3359-3368. http://dx.doi.org/10 .1128/AAC.00054-12.
31. Fenaux M, Eng S, Leavitt SA, Lee Y-J, Mabery EM, Tian Y, Byun D, Canales E, Clarke MO, Doerffler E. 2013. Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob. Agents Chemother. 57:804-810. http://dx.doi.org/10 .1128/AAC.02052-12.
32. Wong KA, Xu S, Martin R, Miller MD, Mo H. 2012. Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Virology 429:57-62. http://dx.doi.org/10.1016/j.virol.2012.03.025.
33. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. 2012. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob. Agents Chemother. 56: 5365-5373. http://dx.doi.org/10.1128/AAC.01256-12.
34. Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney WT, Cheng G. 2013. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res. 100: 439-445. http://dx.doi.org/10 .1016/j.antiviral.2013.08.018.
35. Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, Wakita T. 2013. Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 144:56.e7-58.e7. http://dx.doi.org/10 .1053/j.gastro.2012.09.017.
36. Frank C, Mohamed MK, Strickland GT, Lavanchy D, Arthur RR, Magder LS, El Khoby T, Abdel-Wahab Y, Aly Ohn ES, Anwar W, Sallam I. 2000. The role of parenteral antischistosomal therapy in the spread of hepatitisCvirus in Egypt. Lancet 355:887-891. http://dx.doi.org /10.1016/S0140-6736(99)06527-7.
37. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. 2000. Genetic epidemiology of hepatitis C virus throughout Egypt. J. Infect. Dis. 182: 698-707. http://dx.doi.org/10.1086/315786.
38. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R. 1994. Geographical distribution of hepatitisCvirus genotypes in blood donors: an international collaborative survey. J. Clin. Microbiol. 32:884-892.
39. Chowdhury A, Santra A, Chaudhuri S, Dhali GK, Maity SG, Naik TN, Bhattacharya SK, Mazumder DN. 2003. Hepatitis C virus infection in the general population: a community-based study in West Bengal, India. Hepatology 37:802-809. http://dx.doi.org/10.1053/jhep.2003.50157.
40. White PA, Zhai X, Carter I, Zhao Y, Rawlinson WD. 2000. Simplified hepatitis C virus genotyping by heteroduplex mobility analysis. J. Clin. Microbiol. 38:477-482.
41. Luo G, Hamatake RK, Mathis DM, Racela J, Rigat KL, Lemm J, Colonno RJ. 2000. De novo initiation of RNA synthesis by the RNAdependent RNA polymerase (NS5B) of hepatitis C virus. J. Virol. 74:851-863. http://dx.doi.org/10.1128/JVI.74.2.851-863.2000.
42. Zhong W, Uss AS, Ferrari E, Lau JY, Hong Z. 2000. De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. J. Virol. 74:2017-2022. http://dx.doi.org/10.1128/JVI.74.4.2017-2022 .2000.
43. Kao CC, Singh P, Ecker DJ. 2001. De novo initiation of viral RNAdependent RNA synthesis. Virology 287:251-260. http://dx.doi.org/10 .1006/viro.2001.1039.
44. Harrus D, Ahmed-El-Sayed N, Simister PC, Miller S, Triconnet M, Hagedorn CH, Mahias K, Rey FA, Astier-Gin T, Bressanelli S. 2010. Further insights into the roles of GTP and the C terminus of the hepatitis C virus polymerase in the initiation of RNA synthesis. J. Biol. Chem. 285: 32906-32918. http://dx.doi.org/10.1074/jbc.M110.151316.
45. Scrima N, Caillet-Saguy C, Ventura M, Harrus D, Astier-Gin T, Bressanelli S. 2012. Two crucial early steps in RNA synthesis by the hepatitis C virus polymerase involve a dual role of residue 405. J. Virol. 86:7107-7117. http://dx.doi.org/10.1128/JVI.00459-12.
46. Mosley RT, Edwards TE, Murakami E, Lam AM, Grice RL, Du J, Sofia MJ, Furman PA, Otto MJ. 2012. Structure of hepatitis C virus polymerase in complex with primer-template RNA. J. Virol. 86:6503-6511. http://dx .doi.org/10.1128/JVI.00386-12.
47. Yi G, Deval J, Fan B, Cai H, Soulard C, Ranjith-Kumar CT, Smith DB, Blatt L, Beigelman L, Kao CC. 2012. Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir. Antimicrob. Agents Chemother. 56:830-837. http://dx.doi.org/10 .1128/AAC.05438-11.
48. Tomei L, Altamura S, Bartholomew L, Bisbocci M, Bailey C, Bosserman M, Cellucci A, Forte E, Incitti I, Orsatti L. 2004. Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. J. Virol. 78:938-946. http://dx.doi.org/10.1128/JVI.78.2.938-946.2004.
49. Eltahla AA, Lackovic K, Marquis C, Eden JS, White PA. 2013. A fluorescence-based high-throughput screen to identify small compound inhibitors of the genotype 3a hepatitis C virusRNApolymerase. J. Biomol. Screen. 18:1027-1034. http://dx.doi.org/10.1177/1087057113489883.
50. Jones LA, Clancy LE, Rawlinson WD, White PA. 2006. High-affinity aptamers to subtype 3a hepatitis C virus polymerase display genotypic specificity. Antimicrob. Agents Chemother. 50:3019-3027. http://dx.doi .org/10.1128/AAC.01603-05.
51. Vrolijk JM, Kaul A, Hansen BE, Lohmann V, Haagmans BL, Schalm SW, Bartenschlager R. 2003. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 110:201-209. http://dx.doi.org/10.1016/S0166-0934(03)00134-4.
52. Jones DM, Domingues P, Targett-Adams P, McLauchlan J. 2010. Comparison of U2OS and Huh-7 cells for identifying host factors that affect hepatitis C virus RNA replication. J. Gen. Virol. 91:2238-2248. http://dx .doi.org/10.1099/vir.0.022210-0.
53. Street A, Macdonald A, McCormick C, Harris M. 2005. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular -catenin and stimulation of ß -catenin-responsive transcription. J. Virol. 79:5006-5016. http://dx.doi.org/10.1128/JVI.79.8 .5006-5016.2005.
54. Legrand-Abravanel F, Nicot F, Izopet J. 2010. New NS5B polymerase inhibitors for hepatitis C. Expert Opin. Invest. Drugs 19:963-975. http: //dx.doi.org/10.1517/13543784.2010.500285.
55. Thompson PA, Patel R, Showalter RE, Li C, Applemon JR, Steffy K. 2008. In vitro studies demonstrate that combinations of antiviral agents that include HCV polymerase inhibitor ANA598 have the potential to overcome viral resistance. Hepatology 48:1164A.
56. Le Pogam S, Seshaadri A, Kosaka A, Chiu S, Kang H, Hu S, Rajyaguru S, Symons J, Cammack N, Nájera I. 2008. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61:1205-1216. http://dx.doi.org/10.1093/jac/dkn085.
57. Le Pogam S, Kang H, Harris SF, Leveque V, Giannetti AM, Ali S, Jiang WR, Rajyaguru S, Tavares G, Oshiro C, Hendricks T, Klumpp K, Symons J, Browner MF, Cammack N, Najera I. 2006. Selection and characterization of replicon variants dually resistant to thumb- and palmbinding nonnucleoside polymerase inhibitors of the hepatitis C virus. J. Virol. 80:6146-6154. http://dx.doi.org/10.1128/JVI.02628-05.
58. Shi ST, Herlihy KJ, Graham JP, Nonomiya J, Rahavendran SV, Skor H, Irvine R, Binford S, Tatlock J, Li H. 2009. Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 53: 2544-2552. http://dx.doi.org/10.1128/AAC.01599-08.
59. Ahn J, Flamm SL. 2014. Frontiers in the treatment of hepatitis C virus infection. Gastroenterol. Hepatol. 10:90-100.
60. Delang L, Vliegen I, Froeyen M, Neyts J. 2011. Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. Antimicrob. Agents Chemother. 55:4103-4113. http://dx.doi.org/10.1128/AAC.00294-11.
61. Rodriguez-Torres M, Lawitz E, Cohen D, Larsen LM, Menon R, Collins C, Marsh T, Gibbs S, Bernstein B. 2009. Treatment-naïve, HCV genotype 1-infected subjects show significantly greater HCV RNA decreases when treated with 28 days of ABT-333 plus peginterferon and ribavirin compared to peginterferon and ribavirin alone. Hepatology 50:5A.
62. Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee Y-J, Chan K, Mo H, Delaney W, IV, Cheng G. 2013. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res. 100:439-445. http://dx.doi.org/10.1016/j .antiviral.2013.08.018.
63. Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Gennari N, Bisbocci M, Incitti I, Orsatti L, Harper S, Stansfield I, Rowley M, De Francesco R, Migliaccio G. 2003. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77:13225-13231. http://dx.doi.org/10.1128/JVI.77.24.13225-13231 .2003.
64. Rydberg EH, Cellucci A, Bartholomew L, Mattu M, Barbato G, Ludmerer SW, Graham DJ, Altamura S, Paonessa G, De Francesco R. 2009. Structural basis for resistance of the genotype 2b hepatitis C virus NS5B polymerase to site A non-nucleoside inhibitors. J. Mol. Biol. 390:1048-1059. http://dx.doi.org/10.1016/j.jmb.2009.06.012.
65. Love RA, Parge HE, Yu X, Hickey MJ, Diehl W, Gao J, Wriggers H, Ekker A, Wang L, Thomson JA. 2003. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77:7575-7581. http://dx.doi.org/10 .1128/JVI.77.13.7575-7581.2003.
66. Winquist J, Abdurakhmanov E, Baraznenok V, Henderson I, Vrang L, Danielson UH. 2013. Resolution of the interaction mechanisms and characteristics of non-nucleoside inhibitors of hepatitis C virus polymerase. Antiviral Res. 97:356 -368. http://dx.doi.org/10.1016/j.anti viral.2012.12.027.
67. Hebner CM, Han B, Brendza KM, Nash M, Sulfab M, Tian Y, Hung M, Fung W, Vivian RW, Trenkle J, Taylor J, Bjornson K, Bondy S, Liu X, Link J, Neyts J, Sakowicz R, Zhong W, Tang H, Schmitz U. 2012. The HCV non-nucleoside inhibitor tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function. PLoS One 7:e39163. http://dx .doi.org/10.1371/journal.pone.0039163.
68. Biswal BK, Cherney MM, Wang M, Chan L, Yannopoulos CG, Bilimoria D, Nicolas O, Bedard J, James MNG. 2005. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by nonnucleoside inhibitors. J. Biol. Chem. 280:18202-18210. http://dx.doi.org /10.1074/jbc.M413410200.
69. Biswal BK, Wang M, Cherney MM, Chan L, Yannopoulos CG, Bilimoria D, Bedard J, James MN. 2006. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J. Mol. Biol. 361:33-45. http://dx.doi.org/10.1016 /j.jmb.2006.05.074.
70. Shim JH, Larson G, Wu JZ, Hong Z. 2002. Selection of 3=-template bases and initiating nucleotides by hepatitisCvirus NS5B RNA-dependentRNA polymerase. J. Virol. 76:7030-7039. http://dx.doi.org/10.1128/JVI.76.14 .7030-7039.2002.
71. Ferrari E, He Z, Palermo RE, Huang H-C. 2008. Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation. J. Biol. Chem. 283:33893-33901. http://dx.doi.org/10.1074 /jbc.M803094200.
72. Jiang M, Zhang EZ, Ardzinski A, Tigges A, Davis A, Sullivan JC, Nelson M, Spanks J, Dorrian J, Nicolas O, Bartels DJ, Rao BG, Rijnbrand R, Kieffer TL. 2014. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor. Antimicrob. Agents Chemother. 58:5456-5465. http://dx.doi.org/10.1128/AAC.03052-14.